SNT/FRS2 is a lipid anchored docking protein that contains an amino-terminal myristylation signal, followed by a phosphotyrosine-binding (PTB) domain and a carboxy-terminal region with multiple tyrosine residues. Here we show that the SNT/FRS2 PTB domain binds to RET receptor tyrosine kinase activated by glial cell linederived neurotrophic factor (GDNF) or multiple endocrine neoplasia (MEN) 2 mutations. Analyses by site directed-mutagenesis revealed that it binds to tyrosine 1062 in RET that is also known to be a binding site for the SHC adaptor protein. Whereas SHC bound to RET was associated with GRB2 and GAB1 proteins, SNT/ FRS2 was associated with GRB2 only, suggesting that SNT/FRS2 is involved mainly in the activation of the RAS/mitogen activated protein kinase (MAPK) pathway but not the phosphatidylinositol 3-kinase (PI3-K)/AKT pathway. In addition, phosphorylated SNT/FRS2 appeared to directly complex with SHP-2 tyrosine phosphatase. These results suggest that tyrosine 1062 in RET provides a site for the interaction of multiple signaling molecules and that the balance of SHC and SNT/FRS2 binding may aect the nature of the intracellular signaling for cell proliferation, dierentiation and survival induced by activated RET. Oncogene (2001) 20, 1929 ± 1938 
Introduction
Suc1-associated neurotrophic factor-induced tyrosinephosphorylated target (SNT) was ®rst identi®ed as a protein of apparent molecular mass of 78 ± 90 kDa that binds to p13 suc1 -agarose and is rapidly phosphorylated on tyrosine following stimulation with nerve growth factor (NGF) and ®broblast growth factor (FGF) in the PC12 pheochromocytoma cell line (Rabin et al., 1993) . SNT was described as the speci®c target of dierentiation factor-induced tyrosine kinase activity, because NGF and FGF induce the dierentiation and the cessation of cell division but epidermal growth factor (EGF) that induces proliferation without dierentiation does not phosphorylate tyrosine of SNT. FGF Receptor Substrate 2 (FRS2) was identi®ed as a lipid-anchored docking protein that forms a complex with GRB2/SOS linking FGF-receptor activation to the RAS/MAPK signaling pathway (Kouhara et al., 1997) . Because anti-FRS2 antibody and p13-agarose beads recognized the same tyrosine-phosphorylated GRB2-associated protein, it turned out that FRS2 is identical to SNT (Kouhara et al., 1997) . Two members of the SNT/FRS2 family, SNT1/FRS2a and SNT2/FRS2b that showed 49% identity of the amino acid sequence, have been cloned so far (Xu et al., 1998; Ong et al., 2000) .
SNT/FRS2 contains a myristylation sequence at the amino-terminus, followed by a phosphotyrosine binding (PTB) domain and a carboxy-terminal region with multiple tyrosine residues. In response to FGF or NGF stimulation, the SH2 domain of GRB2 binds to four tyrosine residues present in the carboxy-terminal region of SNT/FRS2 and the amino-terminal SH2 domain of SHP-2 binds to two tyrosine residues (Kouhara et al., 1997; Hadari et al., 1998) . Interestingly, it has been shown that the binding sites for the PTB domain of SNT/FRS2 are dierent between FGF receptor (FGFR) and NGF receptor (TRKA) (Xu et al., 1998; Ong et al., 2000) . Its PTB domain binds to the NPQpY sequence (amino acids 487 ± 490) in the juxtamembrane region of TRKA depending on NGF stimulation whereas it binds constitutively to the juxtamembrane region of FGFR that does not include tyrosine residues.
The RET proto-oncogene encodes a receptor tyrosine kinase the ligands of which are members of the glial cell line-derived neurotrophic factor (GDNF) protein family (Takahashi et al., 1988; Airaksinen et al., 1999) . We and others recently demonstrated that a variety of intracellular signals such as the RAS/MAPK and PI3-K/AKT pathways are transduced through tyrosine 1062 in the carboxy-terminal tail of RET (Hayashi et al., 2000; Segoun-Cariou and Billaud, 2000; De Vita et al., 2000; Besset et al., 2000) . In addition, we found that the signaling through tyrosine 1062 is critical for transforming activity of all multiple endocrine neoplasia (MEN) 2 mutant forms of RET Ishiguro et al., 1999; Iwashita et al., 1999 Iwashita et al., , 2000 . It turned out that tyrosine 1062 represents a binding site for the SHC adaptor protein Arighi et al., 1997; Lorenzo et al., 1997; Ohiwa et al., 1997; Durick et al., 1998; Geneste et al., 1999) and that phosphorylated SHC complexes with both GRB2 and GAB1 proteins in response to GDNF stimulation, leading to the activation of RAS/MAPK and PI3-K/ AKT signaling pathways respectively (Hayashi et al., 2000) . Califano et al. (2000) recently reported that RET with MEN2 mutations interacted with SNT/FRS2. Since the sequence (IENKL) amino-terminal to tyrosine 1062 matches the consensus sequence for binding of the SHC PTB domain , it is possible that the PTB domain of SNT/FRS2 also binds to the same sequence in RET depending on the ligand stimulation and plays a role in the signal transduction. Here we show that SNT/FRS2 binds to tyrosine 1062 in RET activated by GDNF or MEN2 mutations, and complexes with GRB2 adaptor protein and SHP-2 tyrosine phosphatase.
Results

Binding of SNT1/FRS2a to tyrosine 1062 in RET receptor tyrosine kinase in vitro
To investigate the binding ability of SNT1/FRS2a to RET by the pull-down assays, we produced fusion proteins composed of glutathione-S-transferase (GST) and the full sequence or PTB domain of SNT1/FRS2a. As a control, the GST-SHC(full-length) or GST-SHC(PTB domain) fusion proteins were also generated ( Figure 1a ). When SK-N-SH and TGW human neuroblastoma cell lines expressing RET were treated with GDNF and their lysates were incubated with these fusion proteins, it turned out that all four fusion proteins were able to bind to 175 kDa phosphorylated RET in a GDNF-dependent manner (Figure 1b) . On the other hand, the GST-fusion proteins containing the carboxy-terminal region with multiple tyrosine residues of SNT1/FRS2a did not bind to activated RET proteins (data not shown).
To next investigate whether tyrosine 1062 in RET that is known to be a binding site for the SHC PTB domain is also required for the SNT1/FRS2a binding, we replaced tyrosine 1062 in RET long isoform (RET51 type in Figure 2a ) with phenylalanine (designated Y1062F) and established the SK-N-MC human primitive neuroectodermal tumor cells expressing wild-type RET or RET with the Y1062F mutation ( Figure 2c ). The pull-down assays showed that the binding of GST-SNT1/FRS2a or GST-SHC fusion proteins to 175 kDa RET phosphorylated by GDNF was almost abolished by the Y1062F mutation ( Figure  2c ), indicating that tyrosine 1062 represents a binding site for the SNT1/FRS2a PTB domain. The importance of tyrosine 1062 for SNT1/FRS2a binding to RET was further con®rmed using the lysates from NIH3T3 cells expressing RET(Y1062F) proteins with a MEN2A (Cys634?Arg, C634R) or MEN2B (Met918?Thr, M918T) mutation (Figure 2a,d ). On the other hand, Figure 1 Binding of GST-SNT1/FRS2a and GST-SHC fusion proteins to RET activated by GDNF. (a) GST fusion proteins used in this study. The designated GST fusion proteins were separated on SDS-10% polyacrylamide gels and stained with Coomassie Brilliant Blue (CBB). The molecular mass of the fusion proteins was indicated by arrows. These GST fusion proteins were detected by immunoblotting with anti-GST antibody (data not shown). (b) Binding of GST-SNT1/FRS2a or GST-SHC fusion proteins to RET in vitro. SK-N-SH and TGW human neuroblastoma cells were serum-starved for 6 h and treated with GDNF (100 ng/ml) for 10 min. The lysates from GDNF-treated or untreated cells were incubated with the designated GST fusion proteins plus glutathione beads. Bound proteins were separated on SDS-10% polyacrylamide gels and subjected to immunoblotting with anti-RET51 antibody (upper and middle panels). The RET expression in SK-N-SK and TGW cells and its phosphorylation induced by GDNF are shown (lower panel). 175 and 155 kDa RET proteins are indicated replacement of tyrosine 981, 1015 or 1029 with phenylalanine did not aect the binding ability of SNT1/FRS2a to RET, although replacement of tyrosine 905 markedly decreased the binding of SNT1/FRS2a (Figure 2a ,e). As we previously reported , the Y905F mutation strongly diminished the RET tyrosine kinase activity.
Asparagine at the 73 position and a hydrophobic amino acid at the 75 position relative to tyrosine 1062 are known to be important for binding of the SHC PTB domain (Figure 2b ). To investigate the importance of this sequence for the SNT1/FRS2a binding, we changed asparagine at the 73 position (codon 1059 in RET) to alanine and isoleucine at the 75 position (codon 1057) to serine as previously described . These mutations were introduced into RET cDNA with the MEN2A (C634R) mutation and the resulting mutant RET genes were expressed in NIH3T3 cells. The N1059A mutation markedly impaired the binding of both GST-SNT1/ FRS2a and GST-SHC fusion proteins to RET although the impairment by the I1057S mutation was weaker than that by the N1059A mutation ( Figure 3 ). This result thus indicates that SNT1/FRS2a uses the same consensus sequence for its binding to RET as SHC does.
Binding affinity of SNT/FRS2 to three RET isoforms
RET is known to be translated as three isoforms of 1114 amino acids (long isoform; designated RET51 type), 1072 amino acids (short isoform; RET9 type) and 1106 amino acids (middle isoform; RET43 type) that are generated by alternative splicing in the 3'-region downstream of tyrosine 1062 (Figure 2a,b) . We investigated the binding ability of SNT1/FRS2a or SHC to each RET isoform in vitro, using the GSTfusion proteins. Both GST-SNT1/FRS2a and GST-SHC fusion proteins bound to each isoform although the binding anity appeared to be dierent depending on the isoforms (Figure 4 ). That is, the binding anity was signi®cantly low for the RET43 isoform. We obtained similar results from repeated experiments, suggesting that, in addition to the consensus sequence amino-terminal to tyrosine 1062, the carboxy-terminal sequences that are dierent in each isoform ( Figure 2b ) may also in¯uence the binding anity for SHC and SNT/FRS2 proteins.
In vivo association of SNT1/FRS2a with RET and characterization of downstream signaling
To examine the association of SNT1/FRS2a with RET in vivo, the lysates from NIH3T3 cells expressing RET-MEN2A or RET-MEN2B mutant proteins were immunoprecipitated with anti-SNT1/FRS2a antibody, followed by immunoblotting with anti-RET, anti-SNT1/FRS2a or anti-phosphotyrosine antibody. As shown in Figure 5a , phosphorylated RET and SNT1/ FRS2a were co-immunoprecipitated, showing the in vivo association of these two proteins. Similar experiments were performed using anti-SHC antibody for the immunoprecipitation. The mutant RET proteins were more eciently co-immunoprecipitated with SHC than SNT1/FRS2a, suggesting that the binding anity of SHC might be higher than that of SNT1/FRS2a. The coimmunoprecipitation of SNT1/FRS2a or SHC with RET was almost undetectable using the lysates from NIH3T3 cells expressing RET-MEN2A(Y1062F) or RET-MEN2B(Y1062F) mutant proteins (Figure 5a) . Moreover, the association of phosphorylated RET with SNT1/FRS2a or SHC was detected in GDNF-treated SK-N-SH and SK-N-MC(RET) cells but not in GDNFtreated SK-N-MC(RET-Y1062F) cells (Figure 5b ).
Because we recently reported that SHC was associated with GAB1 and GRB2 proteins in a GDNF-dependent manner, resulting in the activation of the PI3-K/AKT and RAS/MAPK signaling pathways respectively (Hayashi et al., 2000) , the association of SNT1/FRS2a with them was further investigated. As shown in Figure 6a , GAB1 was highly phosphorylated on tyrosine in GDNF-treated SK-N-SH and SK-N-MC(RET) cells. The phosphorylated GAB1 was eciently co-immunoprecipitated with SHC but not with SNT1/FRS2a (Figure 6a ). This result was con®rmed by immunoprecipitation with anti-GAB1 antibody, followed by immunoblotting with anti-SNT1/FRS2a antibody or anti-SHC antibody ( Figure  6b ). On the other hand, GRB2 was associated with both SNT1/FRS2a and SHC in a GDNF-dependent manner (Figure 6c ).
Finally, we examined the association of SHP-2 tyrosine phosphatase with SHC or SNT1/FRS2a. In response to GDNF stimulation, SHP-2 was coimmunoprecipitated with SNT1/FRS2a (Figure 6d ). It also appeared to be associated with SHC at a low level (Figure 6d ). Rather, because SHP-2 was strongly associated with phosphorylated GAB1 (Figure 6a,d) , this suggested that the interaction of SHC with SHP-2 could be mediated by GAB1.
Discussion
In the present study, we demonstrated that tyrosine 1062 in RET activated by GDNF or MEN2 mutations represents a binding site for SNT1/FRS2a as well as SHC. SNT1/FRS2a is composed of an amino-terminal myristylation signal, a PTB domain and a carboxyterminal region with multiple tyrosine residues ( Kouhara et al., 1997; Hadari et al., 1998) . As expected, the PTB domain of SNT1/FRS2a was necessary for binding to tyrosine 1062, consistent with the fact that the sequence (IENKL) amino-terminal to tyrosine 1062 matches the consensus sequence for binding of the SHC PTB domain (Ohiwa et al., 1997) . Similar results were also reported for nerve growth factor receptor, that is, tyrosine 499 present in its juxtamembrane region of mouse TrkA was a binding site for both SHC and SNT1/FRS2a PTB domains (Meakin et al., 1999) . Moreover, in the cases of insulin and insulin-like growth factor receptors, the PTB domains of SHC, IRS-1 and IRS-2 appeared to recognize the same tyrosine residue present in their b-chains Gustafson et al., 1995; He et al., 1996) . Because these molecules bound to the NXXpY motif, this suggested that a single phosphorylated tyrosine residue in this motif can bind the PTB domains of multiple adaptor proteins.
In addition, we found that the binding anity of SNT1/FRS2a is dierent among three RET isoforms despite the presence of the NXXpY motif. The pulldown assay showed that its anity to RET43 isoform was signi®cantly low as compared with that to RET9 or RET51 isoform. Using GST-SHC (full-length) and GST-SHC(PTB) fusion proteins, we obtain similar results ; this study). These ®ndings thus suggested the possibility that the sequence carboxy-terminal to tyrosine 1062 may also play a role in binding of SHC and SNT1/FRS2a PTB domains.
We and others recently reported that phosphorylated SHC bound to RET interacted with GRB2 and GAB1/ 2 proteins (Hayashi et al., 2000; Besset et al., 2000) . In response to GDNF stimulation, the GRB2/SOS complex is recruited to phosphorylated SHC, leading to the activation of the RAS/MAPK signaling pathway. On the other hand, GAB1 interacted with SHC and GRB2 is further associated with p85 subunit of PI3-K, leading to the activation of the PI3-K/AKT signaling pathway (Murakami et al., 1999b; Hayashi et , 2000) . Interestingly, SNT1/FRS2a interacted with GRB2 but not GAB1, suggesting that SNT1/FRS2a is not involved in the activation of PI3-K/AKT pathway. Meakin et al. (1999) reported that SNT1/FRS2a competed with SHC for binding to mouse TrkA at tyrosine 499. The SNT1/FRS2a PTB domain competed for binding to TrkA with an EC 50 requiring a 2 ± 5-fold excess of the SHC PTB domain in vitro. Thus, it is possible that SNT/FRS2 and SHC may also compete for binding to RET at tyrosine 1062, although the binding anity of SNT/FRS2 to RET seemed to be weaker than that of SHC, judging from the results of the immunoprecipitation experiments. In the GDNF/ RET signaling system, the dierence in the expression levels of SHC and SNT/FRS2 in RET-positive cells during embryogenesis might aect the activation levels of the RAS/MAPK and PI3-K/AKT signaling pathways that are involved in the regulation of cell proliferation, dierentiation and survival. In this respect, it should be noted that SNT/FRS2 is anchored to the plasma membrane by myristylation at the amino-terminus and its activity is impaired without myristylation (Kouhara et al., 1997) , while SHC is recruited to receptors from the cytoplasm. The dierence in cellular localization of the adaptor proteins may also play a role in the regulation of the intracellular signaling through activated RET. The signal transduction downstream of tyrosine 1062 in RET is quite complicated because a variety of signaling including the RAS/MAPK, PI3-K/AKT, p38MAPK and JNK pathways appeared to be activated through this tyrosine (Hayashi et al., 2000) . At present, how the p38MAPK and JNK pathways are activated by GDNF is unknown. It is possible that the complex formation consisting of SHC, GRB2 and GAB1/2 or of SNT1/FRS2a and GRB2 is required for the activation of these signaling pathways. Alternatively, binding of other docking proteins to tyrosine 1062 may be essential for their activation. Moreover, because SHP-2 tyrosine phosphatase is phosphorylated on tyrosine (data not shown) and associated with SNT1/FRS2a and GAB1 in response to GDNF stimulation, it is of particular interest to elucidate its role in the signal transduction. Hadari et al. (1998) reported that SHP-2 activation and binding to FRS2 are essential for sustained activation of MAPK and for potentiation of FGF-induced PC12 cell dierentiation. In addition, although overexpression of SHP-2 in PC12 cells did not enhance NGFinduced dierentiation, overexpression of a catalytically inactive SHP-2 decreased its dierentiation (Wright et al., 1997) , suggesting an important role of SHP-2 in neuronal dierentiation. Further investigation will elucidate a new role in the signaling downstream of tyrosine 1062 that is responsible for biological activities induced by GDNF.
Materials and methods
Cell lines
NIH3T3 mouse ®broblast, SK-N-MC human primitive neuroectodermal tumor, SK-N-SH human neuroblastoma cell lines were grown in DMEM (Life Technologies, Rockville, MD, USA) supplemented with 8% calf serum. NIH3T3 and SK-N-MC cell lines transfected with plasmid DNAs containing c-RET or mutant RET were described previously Ishiguro et al., 1999; Hayashi et al., 2000) . TGW human neuroblastoma cell lines were grown in RPMI 1640 (Life Technologies) supplemented with 10% fetal calf serum.
Antibodies and growth factor
Rabbit polyclonal anti-RET antibody was raised against a synthetic peptide of carboxyl-terminal 19 amino acids of the long isoform (RET51 type). Mouse monoclonal anti-RET antibody (R5) was raised against the RET extracellular domain (Takahashi et al., 1991) . Mouse monoclonal anti-GST antibody conjugated with horseradish peroxidase (HRP) (B-14) , and rabbit polyclonal anti-FRS2 (H-91) and anti-SH-PTP-2 (C-18) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse monoclonal anti-phosphotyrosine antibody (4G10) and rabbit polyclonal anti-GAB1 antibody were purchased from Upstate Biotechnology (Lake Placid, NY, USA). Rabbit polyclonal and mouse monoclonal anti-SHC antibodies, and mouse monoclonal anti-GRB2 antibody were purchased from Transduction Laboratories (Lexington, KY, USA). HRP-conjugated swine anti-rabbit IgG and HRP-conjugated rabbit anti-mouse IgG secondary antibodies were purchased from DAKO (Carpinteria, CA, USA). GDNF was purchased from PeproTech (London, UK).
Western blotting
Cells were lysed in sodium dodecyl sulfate (SDS) sample buer (20 mM Tris-HCl (pH 6.8), 2 mM EDTA-2Na, 2% SDS, 10% sucrose, 20 mg/ml bromophenol blue (BPB)). The concentration of each lysate was measured using BCA protein assay kit (Pierce, Rockford, IL, USA). After adding dithiothreitol (DTT) at a ®nal concentration of 80 mM, the lysates were boiled for 3 min. Equal protein amounts of the lysates were subjected to SDS-10% polyacrylamide gel electrophoresis (PAGE) and transferred to polyvinylidene di¯uoride (PVDF) membranes (Millipore, Bedford, MA, USA). Membranes were blocked for 1 h at room temperature in 3% albumin in TPBS (phosphate buered saline containing 0.5% Tween-20) with gentle shaking and incubated with primary antibodies overnight at 48C. After washing the membranes with TPBS three times, they were incubated with the secondary antibodies conjugated to horseradish peroxidase for 1 h at room temperature. The reaction was examined by an enhanced chemiluminescence detection kit (ECL, Amersham Pharmacia Biotech, Buckinghamshire, UK) according to the directions of the supplier.
In vitro binding assay using glutathione-S-transferase (GST)-fused proteins Human FRS2a full-length, PTB domain and carboxyterminal region cDNAs were inserted into the pGEX-4T-3 vector (Amersham Pharmacia Biotech, Uppsala, Sweden). Similarly, human SHC (p52 isoform) full-length and PTB domain cDNAs were inserted into the pGEX-3X vector as described previously (Ohiwa et al., 1997; Murakami et al., 1999a) . These recombinant plasmids were used to transform Escherichia coli, DH5 a. Bacteria cultures were grown in Luria Bertonia medium containing 50 mg/ml ampicillin and induced with 0.2 to 1 mM isopropyl-b-D-thiogalactopyranoside (IPTG) at 308C for 6 h. The induced GST fusion proteins were incubated with glutathione sepharose beads (Amersham Pharmacia Biotech) and eluted by glutathione. After eliminating glutathione by dialysis using Centricon (Millipore) with 30 mM Tris-HCl buer (pH 7.5), the concentration of each GST fusion protein was measured using the Bio-Rad Dc protein assay kit (Bio-Rad laboratories, Hercules, CA, USA). Cells expressing oncogenic RET or c-RET were grown subcon¯uently in 100 mm dishes and serum-starved for 6 h. The cells that were unstimulated or stimulated with GDNF (100 ng/ml) for 10 min were washed twice with Tris-buered saline (TBS) and lysed in ice-cold radioimmunoprecipitation assay (RIPA) buer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA and 1% Triton X-100) supplemented with one tablet of Complete protease inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany) per 50 ml, 1 mM phenylmethylsulfonyl¯uoride (PMSF) and 1 mM sodium orthovanadate. The cell lysates were centrifuged at 10 000 g for 30 min to remove cell debris. The protein concentration of each supernatant was measured using the BCA protein assay kit (Pierce) and prepared ®nely so that each lysate might contain the same quantity of RET protein. The supernatants were preincubated with GST sepharose beads for 1 h at 48C, and then centrifuged at 500 g for 5 min to remove the beads. The lysates were incubated with 5 mg of GST fused to the PTB domain of SNT/FRS2 or SHC or with 10 mg of GST fused to the fulllength SNT/FRS2 or SHC protein, plus glutathione beads at 48C for 3 h. The glutathione beads were washed with RIPA buer four times. The proteins bound to GST fusion proteins were eluted in SDS-sample buer, subjected to SDS ± PAGE, and immunoblotted with anti-RET antibody as described above.
Immunoprecipitation
Cells were grown subcon¯uently in 100 mm dishes and serum starved for overnight. The cells expressing RET that were unstimulated or stimulated with GDNF (100 ng/ml) for 10 min were lysed in ice-cold RIPA buer and centrifuged at 10 000 g for 30 min. The protein concentration of each supernatant was measured using the BCA protein assay kit (Pierce). The ®nal concentrations of cell lysates were adjusted to be equal. The lysates were preincubated with normal rabbit IgG (Santa Cruz) and protein A sepharose beads (Sigma, St. Louis, MO, USA), and then centrifuged at 500 g for 5 min to remove the beads. One ml of each lysate was incubated with 2 mg of antibody at 48C for 1 h and the resulting immunocomplexes were collected with protein A sepharose beads and washed with RIPA buer four times. The complexes were eluted in SDS sample buer, subjected to SDS ± PAGE, and immunoblotted with antibodies.
